Pestalozzi advises The European Investment Bank on financing agreement with BioVersys
The European Investment Bank (EIB), the lending arm of the European Union, and BioVersys, a privately-owned clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, announced the signing of a EUR 20 million venture debt transaction.
The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR causes the majority of antimicrobial therapies to become obsolete. Due to its potential to trigger a new bacterial pandemic, AMR has been widely recognised as the top priority health threat by the WHO, G7 and G20.
Pestalozzi advised EIB on all Swiss law aspects of this transaction with a team that included
Franz Schubiger (Partner – Corporate / M&A, Life Sciences – pictured), Nils Harbeke (Partner – Tax), Urs Kloeti (Partner – Financial Services), Daniela Fritsch (Associate – Financial Services), Severin Etzensperger (Associate – IP & TMT, Life Sciences)
